Credit Suisse analyst A.J. Rice raised the firm’s price target on Tenet Healthcare to $98 from $92 and keeps an Outperform rating on the shares following quarterly results. The firm notes Tenet reported Q2 adjusted EBITDA of $843M for the quarter, including $8M of grant income. Adjusted EBITDA ex-grant income was $835M, ahead of estimates, with the company increasing its 2023 guidance for adjusted EBITDA to $3.31B-$3.46B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on THC:
- Tenet Healthcare price target raised to $87 from $84 at RBC Capital
- Tenet Healthcare price target raised to $104 from $95 at UBS
- Tenet Healthcare price target raised to $89 from $87 at Stephens
- Tenet Healthcare price target raised to $90 from $83 at Citi
- Tenet Healthcare sees FY23 adjusted EPS $5.18-$6.03